Abstract
To evaluate the role of F-18 FDG PET for staging, therapy management, molecular radiation treatment planning and early therapy response after neoadjuvant chemoradiation and its effect on survival as compared to histopathologic tumor response (regression grade), findings in 76/141 patients (center Bad Berka) with non-small cell lung cancer stage III are analyzed prospectively in an ongoing multicenter trial (LUCAS-MD, principal study center Bad Berka/Jena).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
